1-2 of 2
Pankaj Patel, PhD
Close
Sort by
Journal Articles

Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

Kevin R. Kelly, MD, Asher Chanan-Khan, MD, Leonard T Heffner, MD, George Somlo, MD, David S. Siegel, MD PhD, Todd Zimmerman, MD, Anand Karnad, MD, Nikhil C. Munshi, MD, Sundar Jagannath, MD, Allen L. Greenberg, MD, Sagar Lonial, MD, Vivek Roy, MD, Sikander Ailawadhi, MD, Farima Barmaki-Rad, MD, Shailesh Chavan, MD, Pankaj Patel, PhD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C Anderson, MD
Journal: Blood
Blood (2014) 124 (21): 4736.
https://doi.org/10.1182/blood.V124.21.4736.4736
Published: 2014
Journal Articles

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

Kevin R. Kelly, MD, PhD, Asher Chanan-Khan, MD, George Somlo, MD, Leonard T Heffner, MD, David S Siegel, MD, PhD., Todd M Zimmerman, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Sagar Lonial, M.D., Vivek Roy, M.D., Markus Ruehle, MD, Shailesh Chavan, MD, Pankaj Patel, PhD, Markus Rothenburger, MD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson
Journal: Blood
Blood (2013) 122 (21): 758.
https://doi.org/10.1182/blood.V122.21.758.758
Published: 2013